Drinking alcohol during pregnancy is associated with Foetal Alcohol Spectrum Disorders (FASD), and women who drink at higher levels are more likely to have a baby with FASD.
Efforts to better understand and respond to ‘high risk’ drinking...
ISSUP India in collaboration with the Ministry of Education (MoE), and the Ministry of Social Justice & Empowerment (MSJE) of the Government of India developed a teacher trainer resource module called "NAVCHETNA: A new Consciousness on Life...
The International Society of Substance Use Professionals (ISSUP) Indonesia and the Indonesia International Training and Treatment Centre (ITTC) together hosted the second webinar on "Addiction Prevention for Youth" on Sunday, May 21, 2023...
ISSUP Indonesia organized the Introduction to Evidence-Based Prevention (INEP) Online Course as a national-level training in Indonesia with 17 participants. The training, conducted by Dr.dr. Kristiana Siste, SpKJ, and Dr. Elvina K...
A research was carried out consisting of 4 master's degree graduation works, with mixed descriptive methodology, which deal with the different risk factors that cause students in Guatemala, who fall into problems of use, consumption and...
ISSUP India chapter in collaboration with the Ministry of Education (MoE), the Ministry of Social Justice & Empowerment (MSJE), Government of India developed a teacher trainer resource module called "NAVCHETNA: A new Consciousness on Life...
Alcohol and other drug treatment are generally only provided for individuals, often away from their families. Treatment aims to improve well-being and reduce the harms of substance use and families and communities can play a significant...
The May 2023 Preventive Medicine Grand Rounds (PMGR) features Recovery Kentucky, a social model program that provides housing and recovery services for rural Kentuckians dealing with substance use disorder. The program is led by the...
For Immediate Release: May 23, 2023
Today, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD)...
For Immediate Release: May 24, 2023
Today, the U.S. Food and Drug Administration (FDA) approved the extended-release Brixadi (buprenorphine) subcutaneous (for use under the skin) injection to treat moderate to severe opioid use disorder...
